US stock · figures in US dollars · scored on full-year results
Thermo Fisher Scientific Thermo Fisher Scientific Inc Common Stock
Thermo Fisher Scientific scores 51/100 on fundamentals: in the bottom 43% of 503 scored S&P 500 stocks. Its strongest area is Financial Safety (83/100); its weakest is Price Fairness (0/100). It carries 2 warning flags: Weak Spot, Limited Data.
- Carries a Weak Spot flag
- Carries a Limited Data flag
A financially strong, expensively priced stock, but price fairness needs attention.
Nearby peers
Ranks #36 of 60 in Healthcare by score
One-Minute Summary
Why Thermo Fisher Scientific scores 51
A financially strong, expensively priced stock, but price fairness needs attention.
Business Strength
50Why 50?
No data: Quarterly Momentum
Show 3 charts
Net Profit & Equity, with ROE
Revenue & Net Profit, with Net Margin
Sales grew about 10.5% over 4 years: customers keep spending more with this company.
Profit climbed about 18% over 4 years: the business keeps more money as it grows.
Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)
Sales grew about 13.8% over the last 8 quarters: customers keep spending more with this company.
Profit grew about 12.1% over the last 8 quarters: the business is keeping more of what it earns.
Financial Safety
83Why 83?
Show 2 charts
Debt vs Equity, with D/E ratio
Borrowings grew about 21.9% over 4 years: watch this; rising debt adds pressure in bad times.
Short-term assets vs bills, with Current Ratio
Cash & Dividends
63Why 63?
Show 3 charts
Operating vs Free Cash Flow
The business generates real cash, and more of it each year: a very healthy sign.
Cash vs Total Debt
Dividends per Share, with Yield
Dividends per share have been maintained or raised: management shares the rewards with you.
Price FairnessLowest pillar
0Why 0?
Show chart
Share Price: Weekly Closes (not part of the score)
The share price is up about 23.3% over the past year.
Risk
60Why 60?
No data: Quarterly Consistency
Show chart
Revenue vs Inventory, with Inventory % of Revenue
Sector peers
Thermo Fisher Scientific (TMO) scores 51/100 (Okay) on Score Your Stock's educational fundamentals model: in the bottom 43% of 503 scored S&P 500 stocks.
Its strongest pillar is Financial Safety (83/100); its weakest is Price Fairness (0/100).
Thermo Fisher Scientific ranks #36 of 60 scored Healthcare stocks on Score Your Stock.
Yes. Thermo Fisher Scientific (TMO) has a dividend yield of 0.3%, from dividends with an ex-date in the last 12 months. It pays out 10% of its profit as dividends. Its Cash & Dividends pillar scores 63/100.
From Malaysia, open an account with a broker that offers US shares (many local and app-based brokers do), convert ringgit to US dollars, then buy TMO. US shares trade one share at a time, not in lots of 100. Check the currency conversion fee and US dividend tax (usually 30% withheld for Malaysians) before you buy.
The overall score pools every measure across 5 weighted pillars: Business Strength, Financial Safety, Cash & Dividends, Price Fairness, and Risk. It uses the same rules as our Bursa scores. For banks, Financial Safety checks nonaccrual (impaired) loans, loan loss coverage and the CET1 capital ratio, from the FDIC call report of the group's main bank. Full methodology and the default weights: https://scoreyourstock.com/how. This is an educational tool, not investment advice.
Thermo Fisher Scientific (TMO) is a Healthcare company (Diagnostics & Research). On Score Your Stock's fundamentals check, it scores 51/100, rated Okay. Its biggest strength is Financial Safety (83/100); its main watch-out is Price Fairness (0/100). Shares currently cost about 36 years of its current profit to buy (P/E 36.4×). It also pays back about 0.3% of the share price as dividends each year. Full breakdown and daily-updated score: https://scoreyourstock.com/stocks/us/tmo-thermo-fisher-scientific
Full Financial History
Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.
| Financial Year | Revenue | Net Profit | Operating Cash Flow | Free Cash Flow | CapEx | Cash | Total Debt | Short-Term Debt | Equity | Current Assets | Current Liabilities | Total Assets | Total Liabilities | Inventory | Dividends | Return on Equity (ROE) | Net Profit Margin | Debt-to-Equity | Current Ratio | Interest Coverage | Dividend Payout Ratio | Div yield | P/E Ratio | P/B Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | US$ 47.4b | US$ 7.1b | US$ 9.3b | US$ 7.6b | US$ -1.7b | US$ 4.1b | US$ 42.5b | US$ 3.4b | US$ 52.7b | US$ 23.4b | US$ 15.1b | US$ 113.2b | US$ 60.4b | US$ 5.6b | - | 13% | 15% | 0.8× | 1.6× | 6.1× | 10% | - | - | - |
| 2025 | US$ 44.6b | US$ 6.7b | US$ 7.8b | US$ 6.3b | US$ -1.5b | US$ 9.9b | US$ 39.4b | US$ 3.5b | US$ 53.4b | US$ 28.7b | US$ 15.2b | US$ 110.3b | US$ 56.8b | US$ 5.4b | US$ 172.0m | 13% | 15% | 0.7× | 1.9× | 6.2× | 9% | 0% | 33.2× | 4.2× |
| 2024 | US$ 42.9b | US$ 6.3b | US$ 8.7b | US$ 7.3b | US$ -1.4b | US$ 4.0b | US$ 31.3b | US$ 2.2b | US$ 49.6b | US$ 22.1b | US$ 13.3b | US$ 97.3b | US$ 47.6b | US$ 5.0b | US$ 156.0m | 13% | 15% | 0.6× | 1.7× | 6.1× | 9% | 0% | 31.8× | 4.1× |
| 2023 | US$ 42.9b | US$ 6.0b | US$ 8.4b | US$ 6.9b | US$ -1.5b | US$ 8.1b | US$ 34.9b | US$ 3.6b | US$ 46.7b | US$ 24.6b | US$ 14.0b | US$ 98.7b | US$ 51.9b | US$ 5.1b | US$ 140.0m | 13% | 14% | 0.8× | 1.8× | 5.6× | 9% | 0% | 33.9× | 4.4× |